在急性中风的设置中治疗花红细胞瘤的管理
Solomon Oak1,2, Mahsa Javid1,3,2, Glenda G Callender1
1From the Department of Surgery, Section of Endocrine Surgery, Yale University School of Medicine, New Haven, Connecticut.
AACE clinical case reports
|April 7, 2025
概括
叶红细胞瘤很少表现为中风. 这种情况表明,中风后6周的康复和2周的手术前封锁可能会优化色细胞瘤手术的结果.
科学领域:
- 内分泌学 在内分泌学.
- 神经学 神经学
- 手术瘤学手术瘤学
背景情况:
- 脑卒中是一种不常见的染细胞瘤的初始表现,需要仔细的外科手术管理.
- 目前缺乏关于手术前封锁时间和手术时间的指导方针.
- 管理与中风一起出现的染细胞瘤需要平衡医疗封锁与及时的手术干预,以防止进一步的并发症.
研究的目的:
- 报告一个表现为血性中风出血转变的染细胞瘤病例.
- 讨论这种罕见表现的诊断,管理和临床过程.
- 审查类似病例的文献,并提出最佳的手术前管理策略.
主要方法:
- 详细审查临床数据,患者表现和治疗过程.
- 综合的文献搜索,以寻找与中风相似的染细胞瘤病例.
- 诊断方法的分析,包括计算机断层扫描 (CT) 扫描, катехоламин水平的评估,以及123I标记的金属基胺扫描.
主要成果:
- 该患者出现了中风,严重高血压和心动减速,确诊为染细胞瘤.
- 在 laparoscopic adrenalectomy 之前,在9周的阿尔法阻塞和抗高血压治疗后实现了血液动力学稳定.
- 经历了手术前的稳定性,尽管经历了手术后的高血压发作,但在手术后得到了解决.
结论:
- 对于出现中风的患者,在差异诊断中应考虑feochromocytoma.
- 至少6周的中风后康复和至少2周的手术前正静性低血压可能是有益的.
- 作为中风呈现的染细胞瘤的最佳管理策略需要进一步的调查和共识.
相关概念视频
01:30Adrenergic Agonists: Therapeutic Uses
693
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
693
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
329
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
329
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
107
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
107
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
501
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
501
01:22Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
514
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
514
01:24Parkinson's Disease: Treatment
161
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
161